Starton Holdings, Inc. (STA)
| Market Cap | 236.18M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -9.28M |
| Shares Out | 39.36M |
| EPS (ttm) | -0.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About STA
Starton is a clinical-stage biotechnology company focused on improving standard-of-care therapies for people with cancer through application of our proprietary platform of delivery technology systems. We use continuous delivery of FDA-approved, active ingredients in an attempt to develop and bring products to market in either new indications or with enhanced outcomes in existing indications. In collaboration with our consulting company, McKinsey & Company, we evaluated over 80,000 potential applications to identify those applications where we b... [Read more]
Financial Performance
Financial StatementsNews
Starton Holdings Readies $40 Million IPO For Oncology Drug Treatments Development
Starton Holdings seeks a $40 million IPO to fund clinical-stage cancer drug reformulation and delivery system programs. STA's lead candidate, STAR-LLD, repurposes generic Revlimid via new delivery mod...
Starton IPO Registration Document (S-1)
Starton has filed to go public with an IPO on the NASDAQ.